VenomAb

VenomAb- a biotech startup developing the World's first recombinant antivenins against snakebite envenoming, in order to revolutionise the treatment of snakebites. Disclaimer: Created in 2013, VenomAb closed as a company in 2017, and now continues as a research project under the Tropical Pharmacology Lab at The Danish Technical University. Each year, more than 5 million people worldwide are affected by snakebite, leading to 150,000 deaths and approximately 3 times as many amputations. The only current treatment against snakebite envenoming consists of animal-derived antiserum containing toxin targeting antibodies. In contrast to animal-derived antisera, a recombinant snakebite antivenom is compatible with the human immune system, and the antivenom can be designed to only target medically relevant venom toxins. Recombinant human antivenoms represent safer, more efficacious, and cost-effective treatment options against snakebite.